

## Supplemental Material

### **Clarifying the use of benzylidene protecting group for D-(+)-ribo-1,4-lactone, an essential building block in the synthesis of C-nucleosides.**

Silvana Casati<sup>1</sup>, Paola Rota<sup>2</sup>, Pietro Allevi<sup>2</sup>, Alessandra Mingione<sup>1</sup>, Roberta Ottria<sup>1\*</sup>, Pierangela Ciuffreda<sup>1</sup>

<sup>1</sup> Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milano, Italy; [silvana.casati@unimi.it](mailto:silvana.casati@unimi.it), [alessandra.mingione@unimi.it](mailto:alessandra.mingione@unimi.it), [roberta.ottria@unimi.it](mailto:roberta.ottria@unimi.it), [pierangela.ciuffreda@unimi.it](mailto:pierangela.ciuffreda@unimi.it)

<sup>2</sup> Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Saldini 50, 20122 Milano, Italy; [pietro.allevi@unimi.it](mailto:pietro.allevi@unimi.it), [paola.rota@unimi.it](mailto:paola.rota@unimi.it).





#### **Table of Contents**



**<sup>1</sup>H and <sup>13</sup>C-NMR spectra**



Pag. 2-17


**Table S1-S4**



Pag. 18





























































172.9 135.3 130.0 126.5 126.8 106.6 81.6 80.1 75.9 63.0 24.9 18.2 5.6 5.8







**Table S1.** Energies (E), relative energies ( $\Delta E$ ) in kJ/mol and Boltzmann population distribution at 298 K of conformers of the compound **12R**, in a range of 50 kJ/mol (12 kcal/mol), calculated with a hybrid DFT (B3LYP) approach with 6-31G\* basis set using SM8 (DMSO) solvation model.

E (kJ/mol)	$\Delta E$ (kJ/mol)	% in the population
-2207062.42	0.00	99.99
-2207039.64	22.78	$1.00 \times 10^{-4}$
-2207031.86	30.56	$4.30 \times 10^{-6}$
-2207026.05	36.37	$4.11 \times 10^{-7}$
-2207025.94	36.48	$3.93 \times 10^{-7}$
-2207019.50	42.92	$2.90 \times 10^{-8}$

**Table S2.** Energies (E), relative energies ( $\Delta E$ ) in kJ/mol and Boltzmann population distribution at 298 K of conformers of the compound **12S**, in a range of 50 kJ/mol (12 kcal/mol), calculated with a hybrid DFT (B3LYP) approach with 6-31G\* basis set using SM8 (DMSO) solvation model.

E (kJ/mol)	$\Delta E$ (kJ/mol)	% in the population
-2207059.06	0.00	99.94
-2207038.82	20.24	0.028
-2207038.68	20.39	0.027
-2207027.14	31.92	$2.56 \times 10^{-4}$
-2207027.08	31.98	$2.50 \times 10^{-4}$
-2207022.11	36.95	$3.36 \times 10^{-5}$
-2207021.70	37.36	$2.84 \times 10^{-5}$

**Table S3.** Energies (E), relative energies ( $\Delta E$ ) in kJ/mol and Boltzmann population distribution at 298 K of conformers of the compound **11R**, in a range of 50 kJ/mol (12 kcal/mol), calculated with a hybrid DFT (B3LYP) approach with 6-31G\* basis set using SM8 (CHCl<sub>3</sub>) solvation model.

E (kJ/mol)	$\Delta E$ (kJ/mol)	% in the population
-2207031.58	0.00	84.42
-2207026.44	5.14	10.63
-2207022.56	9.02	2.22
-2207022.02	9.56	1.78
-2207020.38	11.21	0.92
-2207011.68	19.90	0.03

**Table S4.** Energies (E), relative energies ( $\Delta E$ ) in kJ/mol and Boltzmann population distribution at 298 K of conformers of the compound **11S**, in a range of 50 kJ/mol (12 kcal/mol), calculated with a hybrid DFT (B3LYP) approach with 6-31G\* basis set using SM8 (CHCl<sub>3</sub>) solvation model.

E (kJ/mol)	$\Delta E$ (kJ/mol)	% in the population
-2207029.90	0.00	62.68
-2207027.67	2.23	25.45
-2207025.27	4.63	9.68
-2207020.40	9.50	1.36
-2207018.62	11.28	0.66
-2207015.21	14.69	0.17